Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours

Journal of Clinical Pathology

Volumn 58, Issue 2, 2005, Pages 185-189

  Tse, G M K ^a   Tsang, A K H ^a   Putti, T C ^d   Scolyer, R A ^e,f   Lui, P C W ^c   Law, B K B ^b   Karim, R Z ^e,f   Lee, C S ^e,f  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BREAST FIBROADENOMA; CANCER GRADING; CYSTOSARCOMA PHYLLOIDES; DISEASE SEVERITY; ENDOMETRIUM SARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINDLE CELL CARCINOMA; STROMA CELL; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; FEMALE; FIBROADENOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEPRILYSIN; PHYLLODES TUMOR; STROMAL CELLS;

EID: 13244267298     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.020917     Document Type: Article

References (44)

1. Greaves MF, Brown G, Rapson NT, et al. Antisera to acute lymphoblastic leukaemia cells. Clin Immunol Immunopathol 1975;4:67-84.
2. Greaves MF, Hariri G, Newman RA, et al. Selective expression of the common acute lymphoblastic leukaemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood 1983;61:628-39.
3. Weiss IM, Bindl JM, Picozzi VJ, et al. Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukaemia. Blood 1986;67:474-8.
4. Stein H, Lennert K, Feller AC, et al. Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 1984;42:67-147.
5. Gregory CD, Tursz T, Edwards CF, et al. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol 1987;139:313-18.
6. Chu P, Arber DA. Paraffin section detection of CD10 in 505 nonhematopaietic neoplasms. Am J Clin Pathol 2000;113:374-82.
7. Droz D, Zachar D, Charbit L, et al. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol 1990;137:895-905.
8. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000;24:203-10.
9. Dragovic T, Sekosan M, Becker RP, et al. Detection of neutral endopeptidase 24.11 (neprilysin) in human hepatocellular carcinomas by immunocytochemistry. Lab invest 1994;70:107-13.
10. Xiao SY, Wang HL, Hart J, et al. cDNA arrays and immunohistochemistry identification or CD10/CALLA expression in hepatocellular carcinoma. Am J Pathol 2001;159:1415-21.
11. Sato Y, Itoh F, Hinoda Y, et al. Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon. J Gastroenterol 1996;31:12-7.
12. Carrel S, De Tribolet N, Gross N. Expression of HLA-DR and common acute lymphoblastic leukaemia antigens on glioma cells. Eur J Immunol 1982;12:354-7.
13. Brox AG, Lavallee MC, Arseneau J, et al. Expression of common acute lymphoblastic leukaemia-associated antigen on germ cell tumour. Am J Med 1986;80:1249-52.
14. Imai K, Kanzaki H, Fujiwara H, et al. Expression of aminopeptidase N and neutral endopeptidase on the endometrial stromal cells in enaometriosis and adenomyosis. Hum Reprod 1992;7:1326-8.
15. Kanitakis J, Bourchany D, Cloudy A. Expression of the CD10 antigen (neutral endopeptidase) by mesenchymal tumours of the skin. Anticancer Res 2000;20:3539-44.
16. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273-8.
17. Chu PG, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumours: an immunohistochemical comparison of 34 cases. Mod Pathol 2001;14:465-71.
18. Toki T, Shimizu M, Takagi Y, et al. CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol 2002;21:41-7.
19. Mikami Y, Hata S, Kiyokawa T, et al. Expression of CD10 in malignant mullerian mixed tumours and adenosarcomas: an immunohistochemical study. Mod Pathol 2002;15:923-30.
20. Mahendran R, McIlhinney R, O'Hare M, et al. Expression of the common acute lymphoblastic leukaemia antigen (CALLA) in the human breast. Mol Cell Probes 1989;3:39-44.
21. Moritani S, Kushima R, Sugihara H, et al. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002;15:397-405.
22. Iwaya K, Ogawa H, Izumi M, et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002;440:589-93.
23. Mechtersheimer G, Kruger KH, Born IA, et al. Antigenic profile of mammary fibroodenoma and cystosarcoma phyllodes. A study using antibodies to estrogen and progesterone receptors and to a panel of cell surface molecules. Pathol Res Proof 1990;186:427-38.
24. Azzopardi JG. Sarcoma of the breast. In: Bennington J, ed. Problems in breast pathology, Vol. II, Major problems in pathology. Philadelphia: WB Sounders, 1979:355-9.
25. Palmer ML, De Risi DC, Pelikan A, et al. Treatment options and recurrence potential for cystosarcoma phyllodes. Surg Gynecol Obstet 1990;170:193-6.
26. Kario K, Meado S, Mizuno Y, et al. Phyllodes tumour of the breast: a clinocopathologic study of 34 cases. J Surg Oncol 1990;45:46-51.
27. Rowell MD, Perry RR, Hsiu JG, et al. Phyllodes tumours. Am J Surg 1993;165:376-9.
28. Cole-Beuglet C, Soriano R, Kurtz AB, et al. Ultrasound, X-ray mommography and histopathology of cystosarcoma phyllodes. Radiology 1983;146:481-6.
29. Rosen PP. Fibroepithelial neoplasms. In: Breast pathology, 2nd ed. Philadelphia: Lippincott-Raven, 2000:176-97.
30. Tse GM, Putti TC, Kung FY, et al. Increased p53 protein expression in malignant mammary phyllodes tumours. Mod Pathol 2002;15:734-40.
31. Zhu XQ, Shi YF, Cheng XD, et al. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol 2004;92:71-9.
32. Oliva E, Young RH, Amin MB, et al. An immunohostochemical analysis of endometrial stromal and smooth muscle tumours of the uterus. Am J Surg Pathol 2002;26:403-12.
33. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinomas. Mod Pathol 2004;17:646-52.
34. Ogawa H, Iwaya K, Izumi M, et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002;33:806-11.
35. Millar EK, Beretov J, Marr P, et al. Malignant phyllodes tumours of the breast display increased stromal p53 protein expression. Histopathology 1999;34:491-6.
36. Tse GM, Ma TK, Chan KF, et al. Increased microvessel density in malignant and borderline mammary phyllodes tumours. Histopathology 2001;38:567-70.
37. Tse GM, Lui PC, Scolyer RA, et al. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumours. Mod Pathol 2003;16:1007-13.
38. Tse GM, Putti TC, Lui PC, et al. Increased c-kit (CD117) expression in malignant mammary phyllodes tumours. Mod Pathol 2004;17:827-31.
39. Niezabitowski A, Lackowska B, Rys J, et al. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumour of the breast: immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat 2001;65:77-85.
40. Kuenen-Boumeester V, Henzen-Logmans SC, Timmermans MM, et al. Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast. J Pathol 1999;189:169-75.
41. Shabalova IP, Chemeris GJ, Ermilova VD, et al. Phyllodes tumour: cytologic and histologic presentation of 22 cases, and immunohistochemical demonstration of p53. Cytopathology 1997;8:177-87.
42. Suo Z, Nesland JM. Phyllodes tumour of the breast: EGFR family expression and relation to clinicopathological features. Ultrastruct Pathol 2000;24:371-81.
43. Reinfuss M, Mitus J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumour of the breast: an analysis of 179 cases. Cancer 1996;77:910-16.
44. Cohn-Cedermark G, Rutqvist LE, Rosendahl I, et al. Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients. Cancer 1991;68:2017-22.